American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

CheckMate-227: Nivolumab plus Ipilimumab in Advanced NSCLC – Four-Year Update

ASCO 2021 – Lung Cancer

Nivolumab in combination with ipilimumab delivers durable, long-term survival benefit versus chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) regardless of PD-L1 expression with 4 years of follow-up. Read More ›

GEOMETRY Mono-1: Capmatinib in MET Exon 14–Mutated Advanced NSCLC

ASCO 2021 – Lung Cancer

Deep and durable responses with a manageable toxicity profile were achieved with capmatinib treatment in patients with MET exon 14–mutated advanced profile non–small-cell lung cancer (NSCLC) regardless of line of therapy. Read More ›

Videos Year in Review

Key Abstracts from ASCO 2021 in NSCLC

By Mark A. Socinski, MD

AACR & ASCO 2021 – Midyear Review

Dr Mark Socinski reviews a broad variety of studies, including the evolving role of EGFR inhibitors and immunotherapy in NSCLC, the benefits of immunotherapy plus chemotherapy, and the impact of immune-related adverse events on clinical outcomes in NSCLC. Read More ›

ASCO 2020 Lung Cancer Highlights

ASCO 2020 – Lung Cancer

Although the American Society of Clinical Oncology (ASCO) 2020 meeting was held virtually because of the COVID-19 pandemic, hundreds of abstracts, posters, and presentations were still made available to inform clinicians on the latest developments in the treatment of lung cancer. This publication features some of the key highlights from the meeting, which can be used to improve the management and care of patients with the disease.

American Society of Clinical Oncology (ASCO)

Page 7 of 29